A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

BIOLOGICAL: Ad26.Mos4.HIV
BIOLOGICAL: MVA-Mosaic
BIOLOGICAL: Clade C gp140 + Mosaic gp140
DRUG: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.

Collaborators

[object Object]
[object Object]
[object Object]